Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

Part of paid clinical trials in Kansas City, Missouri.

Sponsor
University of Kansas Medical Center
Study ID
NCT05732272
Phase
PHASE3
Status
Recruiting

Conditions

  • Smoking Cessation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Bupropion — DRUG
    150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.

Study Details

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Key Dates

Start date
Feb 28, 2023
Status verified
Feb 2026
Primary completion
Jan 31, 2027
Completion
Apr 30, 2027

Study Design

Enrollment
500 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Standard Treatment
    250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
  • Active Comparator: Extended Treatment
    250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.

Primary Outcome Measure

Verified abstinence at Month 6 [ Time Frame: Month 6 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Kansas Medical CenterKansas CityMissouri64130
Tricia Snow, MPH
816-398-8960

Find similar trials in Kansas City, MO

Related Studies